Curasight has highlighted recently presented results of a phase II study of its gallium-68 (Ga-68) NOTA-AE105 PET radiotracer in patients with brain cancer.
Dr. Aleena Azam, of Copenhagen University Hospital-Rigshospitalet, presented the results in a session at the World Molecular Imaging Congress 2023, held on 5-9 September in Prague. In 24 glioma patients, 22 with high-grade gliomas and two with low-grade gliomas, Ga-68 NOTA-AE105 PET imaging showed high uptake of the tracer by tumors, Curasight said. The high uptake group compared with the low uptake group had a more than 10-fold poorer prognosis, according to the findings.
Curasight has registered the approach under the brand name uTrace.<.p>
